Trial Profile
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RSV F protein vaccine-Novavax (Primary)
- Indications Respiratory syncytial virus infections
- Focus Registrational; Therapeutic Use
- Acronyms Prepare
- Sponsors Novavax
- 30 Jul 2020 Belgium, France, Germany, Italy, India, Mozambique and Netherlands were the planned locations of European Clinical Trials Database.
- 30 Jul 2020 Results published in the New England Journal of Medicine
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.